Andreas, Stefan

[["dc.bibliographiccitation.firstpage","769"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Immunotherapy"],["dc.bibliographiccitation.lastpage","782"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Schiwitza, Annett"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Zwerger, Birgit"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Reinhardt, Christian"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Andreas, Stefan"],["dc.contributor.author","Rittmeyer, Achim"],["dc.date.accessioned","2020-12-10T18:43:39Z"],["dc.date.available","2020-12-10T18:43:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.2217/imt-2019-0039"],["dc.identifier.eissn","1750-7448"],["dc.identifier.issn","1750-743X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78202"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","719"],["dc.bibliographiccitation.issue","43"],["dc.bibliographiccitation.journal","DEUTSCHES ARZTEBLATT INTERNATIONAL"],["dc.bibliographiccitation.lastpage","724"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Andreas, Stefan"],["dc.contributor.author","Rittmeyer, Achim"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Huber, Rudolf Maria"],["dc.date.accessioned","2018-11-07T09:18:29Z"],["dc.date.available","2018-11-07T09:18:29Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Lung cancer is the leading cause of death from cancer in Germany. 90% of cases are due to the inhalation of tobacco smoke. About 40% of patients with newly diagnosed lung cancer are still smokers. A structured smoking cessation program is medically reasonable in this situation but is only rarely offered. Methods: This review is based on a selective search in the PubMed database combined with a manual search for current publications. Results: Many cross-sectional and longitudinal studies have shown that patients with lung cancer benefit from smoking cessation. After resection with curative intent, second tumors are 2.3 times more common, and recurrent tumors 1.9 times more common, in patients who continue to smoke than in those who stop. The overall mortality in smokers is 2.9 times higher. Smoking cessation also lowers the rate of radiation pneumonitis and infection during radiotherapy and prolongs the median survival after chemoradiotherapy for small-cell lung cancer (18.0 vs. 13.6 months). For patients with non-small-cell lung cancer, smoking cessation is associated with a better general state of health (77.5% vs. 57.6%). For the many patients with lung cancer who are treated palliatively, smoking cessation offers the advantages of improved pulmonary function, weight gain, and better overall quality of life. Conclusion: Smoking cessation in patients with lung cancer is an important means of increasing the efficacy of treatment and improving their quality of life."],["dc.identifier.doi","10.3238/arztebl.2013.0719"],["dc.identifier.isi","000326739700001"],["dc.identifier.pmid","24222790"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28421"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Deutscher Aerzte-verlag Gmbh"],["dc.relation.issn","1866-0452"],["dc.title","Smoking Cessation in Lung Cancer-Achievable and Effective"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","252"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Pulmonary Medicine"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Reinhardt, Christian"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Herrmann‐Lingen, Christoph"],["dc.contributor.author","Rittmeyer, Achim"],["dc.contributor.author","Andreas, Stefan"],["dc.date.accessioned","2022-07-01T07:35:22Z"],["dc.date.available","2022-07-01T07:35:22Z"],["dc.date.issued","2022"],["dc.date.updated","2022-07-25T11:18:48Z"],["dc.description.abstract","Purpose Smoking cessation in patients with diagnosed lung cancer has positive effects on cancer therapy and overall prognosis. Despite this, knowledge on smoking cessation in lung cancer patients is sparse. Methods This is an observational single centre, 12-week, prospective, single-arm trial at a tertiary lung cancer centre. Responsive patients were enrolled following confirmed lung cancer diagnosis. Smoking cessation intervention included counselling as well as pharmacotherapy. The primary endpoint was the point prevalence abstinence rate at week 12 based on biochemical verification. Secondary endpoints were the abstinence rate at week 26, quality of life and side effects. Results 80 patients were enrolled. Mean age was 62.6 ± 7.9 years. Most patients (63%) were treated with chemotherapy or radiochemotherapy. 39 patients used nicotine replacement therapy, 35 varenicline whereas six patients did not use pharmacotherapy. During the study period 13 patients died. Data were available in 72 patients after 12 weeks and 57 patients at week 24. Point prevalence abstinence rates were 37.5% (95% CI 26.4–49.7%) at week 12 and 32.8% (95% CI 21.8–45.4%) at week 26, respectively. Quality of life and side effects were not significantly affected by pharmacotherapy. Conclusion In conclusion, our results suggest that smoking cessation is feasible in patients with newly diagnosed lung cancer. The observed abstinence rate is comparable to other patient cohorts. Furthermore, pharmacotherapy in addition to cancer therapy was safe and did not show novel side effects in these seriously ill patients. Thus, smoking cessation should be an integral part of lung cancer treatment. Trial registration The study was conducted in accordance with good clinical practice standards (GCP) and approved by the local ethics committee (16/3/14), the European PAS registry (EUPAS8748) and the German BfArM (NIS-Studien-Nr. 5508). All patients provided written informed consent before study enrollment."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","BMC Pulmonary Medicine. 2022 Jun 27;22(1):252"],["dc.identifier.doi","10.1186/s12890-022-02048-1"],["dc.identifier.pii","2048"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112152"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-581"],["dc.relation.eissn","1471-2466"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject","Smoking cessation"],["dc.subject","Lung cancer"],["dc.subject","Pharmacotherapy"],["dc.subject","Varenicline"],["dc.subject","Real life setting"],["dc.title","Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1445"],["dc.bibliographiccitation.issue","17"],["dc.bibliographiccitation.journal","Immunotherapy"],["dc.bibliographiccitation.lastpage","1461"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Garelli, Elena"],["dc.contributor.author","Rittmeyer, Achim"],["dc.contributor.author","Putora, Paul Martin"],["dc.contributor.author","Glatzer, Markus"],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","Andreas, Stefan"],["dc.date.accessioned","2020-12-10T18:43:39Z"],["dc.date.available","2020-12-10T18:43:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.2217/imt-2019-0105"],["dc.identifier.eissn","1750-7448"],["dc.identifier.issn","1750-743X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78203"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Abscopal effect in lung cancer: three case reports and a concise review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","200300"],["dc.bibliographiccitation.issue","161"],["dc.bibliographiccitation.journal","European Respiratory Review"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Rittmeyer, Achim"],["dc.contributor.author","Schiwitza, Annett"],["dc.contributor.author","Sahovic, Lejla"],["dc.contributor.author","Eul, Bastian"],["dc.contributor.author","Andreas, Stefan"],["dc.date.accessioned","2021-09-01T06:38:27Z"],["dc.date.available","2021-09-01T06:38:27Z"],["dc.date.issued","2021"],["dc.description.abstract","Introduction As incidence rates for lung cancer are still very high and lung cancer remains the most deadly cancer since the turn of the millennium, efforts have been made to find new approaches in cancer research. This systematic review highlights how therapeutic options were extended and how the development of new drugs has picked up speed during the last 20 years. Methods A systematic search was performed in PubMed, Cochrane Library and the European Union Trial Register and 443 records were identified. Our inclusion criteria constituted completed phase I, II and III studies investigating drugs approved by the European Medicines Agency (EMA). Overall, 127 articles were analysed. Results During the 5 year interval from 2015 to 2020, significantly more drugs were approved after phase III, and occasionally after phase II, trials than between 2000 and 2005 (p=0.002). Furthermore, there was a significant time difference (p=0.00001) indicating an increasingly briefer time interval between the publication of phase I and phase III results in the last few years. Discussion Due to novel therapeutic approaches, numerous new drugs in lung oncology were approved. This has improved symptoms and prognoses in patients with advanced lung cancer. However, faster approval could make it difficult to scrutinise new options regarding safety and efficacy with sufficient diligence."],["dc.description.abstract","Introduction As incidence rates for lung cancer are still very high and lung cancer remains the most deadly cancer since the turn of the millennium, efforts have been made to find new approaches in cancer research. This systematic review highlights how therapeutic options were extended and how the development of new drugs has picked up speed during the last 20 years. Methods A systematic search was performed in PubMed, Cochrane Library and the European Union Trial Register and 443 records were identified. Our inclusion criteria constituted completed phase I, II and III studies investigating drugs approved by the European Medicines Agency (EMA). Overall, 127 articles were analysed. Results During the 5 year interval from 2015 to 2020, significantly more drugs were approved after phase III, and occasionally after phase II, trials than between 2000 and 2005 (p=0.002). Furthermore, there was a significant time difference (p=0.00001) indicating an increasingly briefer time interval between the publication of phase I and phase III results in the last few years. Discussion Due to novel therapeutic approaches, numerous new drugs in lung oncology were approved. This has improved symptoms and prognoses in patients with advanced lung cancer. However, faster approval could make it difficult to scrutinise new options regarding safety and efficacy with sufficient diligence."],["dc.identifier.doi","10.1183/16000617.0300-2020"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88935"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-455"],["dc.relation.eissn","1600-0617"],["dc.relation.issn","0905-9180"],["dc.title","Update on recent key publications in lung oncology: picking up speed"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]